Evaxion publishes data, showing 67% objective response rate in metastatic melanoma for the ai-designed personalized cancer vaccine evx-01, in leading medical journal

Copenhagen, denmark, june 17, 2024 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, announces publication of data from its phase 1 dose escalation study of its lead personalized cancer vaccine candidate, evx-01, for metastatic melanoma. the study results, published in the journal for immunotherapy of cancer , demonstrated that eight out of 12 patients (67%) experienced objective clinical responses (orr) with six partial and two complete responses. further, evx-01 immunization did not induce vaccine-related serious adverse events in patients co-administered with anti-pd1 therapy.
EVAX Ratings Summary
EVAX Quant Ranking